Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 5:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 113 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Aminolevulinic Acid Hydrochloride Clear all
Completed Not applicable Interventional

Photodynamic Therapy for Prevention of Nonmelanoma Skin Cancer in Organ Transplant Recipients

NCT02751151
View directory record Official record
Conditions
Nonmelanoma Skin Cancers
Interventions
have Levulan Kerastick (aminolevulinic acid) solution
Other
Lead sponsor
Inova Health Care Services
Other
Eligibility
18 Years to 100 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 6, 2021 · Synced Oct 9, 2026, 5:40 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Treatment of Oral Premalignant Lesions With 5-ALA PDT

NCT00571974
View directory record Official record
Conditions
Leukoplakia, Erythroplakia
Interventions
PDL-585, ScleroPLUS laser, 5-Aminolevulinic Acid (Levulan KerastickTM), Fluorescence Diagnosis Imaging
Device · Drug · Procedure
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 80 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Mar 24, 2015 · Synced Oct 9, 2026, 5:40 AM EDT
Completed Not applicable Interventional Results available

Photodynamic Therapy With Levulan® +/- Topical Retinoid Pre-Treatment In The Treatment Of Actinic Keratoses

NCT01053000
View directory record Official record
Conditions
ACTINIC KERATOSES
Interventions
Tazorac
Drug
Lead sponsor
Stewart, Roger H., M.D., P.A.
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Fort Lauderdale, Florida
Source: ClinicalTrials.gov public record
Updated Aug 11, 2015 · Synced Oct 9, 2026, 5:40 AM EDT
Completed Early Phase 1 Interventional

Pilot Study for the Use of Photodynamic Therapy in the Treatment of Seborrheic Dermatitis

NCT03114111
View directory record Official record
Conditions
Seborrheic Dermatitis
Interventions
aminolevulinic acid (ALA), Placebo
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Aug 11, 2021 · Synced Oct 9, 2026, 5:40 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Superficial Basal Cell Carcinoma (sBCC) With Photodynamic Therapy (PDT).

NCT03573401
View directory record Official record
Conditions
Superficial Basal Cell Carcinoma
Interventions
Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT), Placebo Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient)
Combination Product
Lead sponsor
Biofrontera Inc.
Industry
Eligibility
18 Years and older
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
18
States / cities
Phoenix, Arizona • Fountain Valley, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 9, 2026, 5:40 AM EDT
Completed Phase 2 Interventional Results available

Short-incubation Levulan Photodynamic Therapy Versus Vehicle for Face/Scalp Actinic Keratosis (AK)

NCT01475955
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Broad Area ALA 1-hour incubation, Broad Area ALA 2 hour incubation, broad area ALA 3-hour incubation, Spot ALA 2 hour incubation, Vehicle PDT, Blue Light Treatment
Drug · Device
Lead sponsor
DUSA Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
13
States / cities
La Jolla, California • Los Angeles, California • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2016 · Synced Oct 9, 2026, 5:40 AM EDT
Completed Phase 2 Interventional Results available

Short Contact Protocols to Reduce Pain During 10% ALA Gel Red-light Photodynamic Therapy of Actinic Keratoses

NCT06027619
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Topical aminolevulinate (10% ALA gel), Red light illumination
Drug · Device
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Oct 9, 2026, 5:40 AM EDT
Withdrawn Phase 1 Interventional

A Proof of Principle Study of Aminolevulinic Acid (ALA) - Induced Fluorescence Detection in Resectable Non-Small Cell Lung Cancer

NCT01611584
View directory record Official record
Conditions
Lung Cancer in Normal and Malignant Tumors
Interventions
ALA-induced Fluorescence
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Nov 13, 2014 · Synced Oct 9, 2026, 5:40 AM EDT
Withdrawn No phase listed Observational

Use of 5-Aminolevulinic Acid to Assess Bone and Tissue Profusion in Orthopaedic Infection Patients

NCT04976049
View directory record Official record
Conditions
Trauma, Infection, Bone Fracture
Interventions
Imaging using 5-Aminolevulinic Acid (5-ALA) during surgery
Procedure
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Nov 28, 2022 · Synced Oct 9, 2026, 5:40 AM EDT
Completed Not applicable Interventional Results available

Near Infrared Fluorescence Imaging for Bladder Cancer Detection

NCT03058705
View directory record Official record
Conditions
Bladder Cancer
Interventions
Hexaminolevulinate HCL, Near Infrared Fluorescence (NIRF)
Drug · Device
Lead sponsor
Edward Messing
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Aug 19, 2019 · Synced Oct 9, 2026, 5:40 AM EDT
Completed Phase 1 Interventional

Fluorescence Guided Resection of Brain Tumors

NCT00870779
View directory record Official record
Conditions
Brain Tumors
Interventions
5-aminolevulinic acid
Drug
Lead sponsor
David W. Roberts
Other
Eligibility
21 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jun 14, 2019 · Synced Oct 9, 2026, 5:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Activation of Ameluz With BBL HEROic for the Treatment of Actinic Keratoses and Photodamage

NCT07053852
View directory record Official record
Conditions
Actinic Keratoses, Photodamage
Interventions
Ameluz, Sciton HEROic
Drug · Device
Lead sponsor
Sherrif Ibrahim
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Victor, New York
Source: ClinicalTrials.gov public record
Updated Jan 2, 2026 · Synced Oct 9, 2026, 5:40 AM EDT
Terminated Phase 4 Interventional Results available

Treatment of Actinic Keratoses of the Face With Imiquimod 3.75% Cream Followed by Photodynamic Therapy

NCT01203878
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Photodynamic therapy, Imiquimod
Drug
Lead sponsor
Tennessee Clinical Research Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
3
States / cities
Englewood, Colorado • Charlotte, North Carolina • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 8, 2014 · Synced Oct 9, 2026, 5:40 AM EDT
Not yet recruiting Phase 2 Interventional

A Multicenter Study to Assess the Feasibility of 5-Aminolevulinic Acid (5-ALA) in Pediatric Brain Tumor Patients

NCT06907485
View directory record Official record
Conditions
Pediatric Brain Tumor
Interventions
Aminolevulinic acid hydrochloride
Drug
Lead sponsor
Costas Hadjipanayis
Other
Eligibility
2 Years to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
2
States / cities
Chicago, Illinois • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 9, 2026, 5:40 AM EDT
Completed Phase 2 Interventional

Imaging Procedure Using ALA in Finding Residual Tumor in Grade IV Malignant Astrocytoma

NCT00752323
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
aminolevulinic acid, Surgical Resection
Drug · Procedure
Lead sponsor
Andrew Sloan, MD
Other
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 17, 2021 · Synced Oct 9, 2026, 5:40 AM EDT
Completed Early Phase 1 Interventional

Photodynamic Therapy in Treating Patients With Refractory Mycosis Fungoides

NCT03281811
View directory record Official record
Conditions
Refractory Mycosis Fungoides
Interventions
Aminolevulinic Acid Hydrochloride, Photodynamic Therapy, Quality-of-Life Assessment, Radiation Therapy
Drug · Other · Radiation
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 5, 2023 · Synced Oct 9, 2026, 5:40 AM EDT
Not listed Not applicable Interventional

5-ALA in Recurrent Glioma

NCT02119338
View directory record Official record
Conditions
Glioma
Interventions
5-ala
Drug
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 6, 2017 · Synced Oct 9, 2026, 5:40 AM EDT
Recruiting Phase 2 Interventional

Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma

NCT07225621
View directory record Official record
Conditions
Glioblastoma, GBM
Interventions
5-ALA HCl + LIDU SDT, Placebo + Sham SDT
Combination Product
Lead sponsor
Alpheus Medical, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
11
States / cities
Boston, Massachusetts • Rochester, Minnesota • Albany, New York + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 9, 2026, 5:40 AM EDT
Recruiting Phase 2 Interventional

Photodynamic Diagnosis of Kidney Cancer Using Fluorescence Endoscopy and Oral 5-ALA

NCT07828704
View directory record Official record
Conditions
Kidney Cancers
Interventions
5-Aminolevulinic acid Hydrochloride (Gliolan®)
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 9, 2026, 5:40 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Photodynamic Therapy With Levulan Kerastick + Blue Light for Actinic Keratoses on the Upper Extremities

NCT02137785
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Aminolevulinic Acid (ALA), Topical Solution Vehicle, Blue Light Photodynamic Therapy Illuminator (BLU-U)
Drug · Device
Lead sponsor
DUSA Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
13
States / cities
Fremont, California • San Diego, California • Aventura, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2015 · Synced Oct 9, 2026, 5:40 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Assessment of Skin Lesions Using a Tissue Oxygen Imager Based on Protoporphyrin IX (PPIX) Fluorescence. This is an Open-label, Non-randomized, Feasibility Study That Includes a One-time Application of an FDA Approved Medication Followed by Local Imaging for Benign Skin Growth and Lesions Clinically

NCT07201376
View directory record Official record
Conditions
Non-Melanoma Skin Cancer (NMSC), Benign Skin Growth
Interventions
Ameluz 10% Topical Gel, Protoporphyrin IX
Drug · Device
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 9, 2026, 5:40 AM EDT
Suspended Phase 2 Interventional

A Phase 2 Study of Sonodynamic Therapy Using SONALA-001 and Exablate 4000 Type 2.0 in Patients with DIPG

NCT05123534
View directory record Official record
Conditions
Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma
Interventions
SONALA-001 (ALA) and MR-Guided Focused Ultrasound device (MRgFUS)
Combination Product
Lead sponsor
SonALAsense, Inc.
Industry
Eligibility
5 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
3
States / cities
San Francisco, California • Washington D.C., District of Columbia • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 9, 2026, 5:40 AM EDT
Completed Phase 3 Interventional Results available

Metvix PDT Versus Vehicle PDT With Aktilite CL128 Lamp in Patients With Actinic Keratosis on the Face and Scalp

NCT00304239
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Metvix-PDT, Vehicle-PDT
Combination Product
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
4
States / cities
Naperville, Illinois • Louisville, Kentucky • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2023 · Synced Oct 9, 2026, 5:40 AM EDT
Recruiting Phase 3 Interventional

Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)

NCT05804370
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Gleolan
Drug
Lead sponsor
NX Development Corp
Industry
Eligibility
18 Years and older · Female only
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
11
States / cities
Phoenix, Arizona • Jacksonville, Florida • Annapolis, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 9, 2026, 5:40 AM EDT